valine has been researched along with Diabetes Mellitus, Type 2 in 170 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (4.12) | 18.2507 |
| 2000's | 78 (45.88) | 29.6817 |
| 2010's | 65 (38.24) | 24.3611 |
| 2020's | 20 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Ang, K; Ang, SF; Ching, J; Kovalik, JP; Lee, LS; Lim, SC; Lim, Z; Low, S; Moh, A; Shao, YM; Subramaniam, T; Sum, CF; Tang, WE; Wang, J; Wee, HN | 1 |
| Avtandilyan, N; Grigoryan, A; Javrushyan, H; Maloyan, A; Nadiryan, E | 1 |
| Lenart-Lipinska, M; Matyjaszek-Matuszek, B; Szmygin, H; Szydelko, J; Wozniak, S | 1 |
| Bai, M; Chen, J; Dai, H; Han, F; Lin, W; Wang, J; Weng, C; Xie, X; Zhu, H | 1 |
| Huang, C; Lin, D; Lu, R; Zhang, Y; Zhou, L; Zou, H | 1 |
| Jia, Y; Jiang, T; Li, S; Ren, Z; Wang, J; Wang, L; Wang, Z; Yu, Y | 1 |
| Álvarez, C; Álvarez-Cilleros, D; Amigó, N; Chagoyen, M; Correig, X; Fernández-Millán, E; Martín, MÁ; Ramos, S; Samino, S | 1 |
| Ardavani, A; Atherton, PJ; Idris, I; Mellett, A; Ramzan, I; Vanweert, F | 1 |
| Fujita, Y; Furuya, F; Ikeda, K; Inagaki, N; Isomura, N; Kondo, A; Li, Y; Mano, F; Matsuo, N; Minamino, H; Oguri, Y; Takesue, K | 1 |
| Bjune, MS; Blüher, M; Dankel, SN; Glastad, RC; Johnston, IG; Kern, M; Laupsa-Borge, J; Lawrence-Archer, L; McCann, A; Mellgren, G; Sommersten, CH | 1 |
| Li, HL; Li, ZY; Shen, QM; Tan, YT; Tuo, JY; Wang, J; Xiang, YB | 1 |
| Liu, Z; Wang, J; Zhang, Q; Zhou, C | 1 |
| Berska, J; Bugajska, J; Gotfryd-Bugajska, K; Pasternak, A; Sztefko, K; Szura, M | 1 |
| Choi, HJ; Jeon, HJ; Kim, BJ; Kim, JM; Kim, YJ; Lee, HS; Oh, T; Yu, HY; Yun, JH | 1 |
| Liao, X; Liu, B; Lu, Y; Lyu, Z; Qu, H; Xu, Y; Zhang, L; Zheng, H | 1 |
| Abdel Moneim, A; Mabrouk, D; Mahmoud, B; Suleiman, HA; Zaky, MY | 1 |
| Abed, S; Azoulay, D; Bashkin, A; Kaykov, E; Nodelman, M; Sfadi, A; Shaoul, E; Shehadeh, M; Sheleg, O | 1 |
| Abdel Alem, S; Abdellatif, Z; Abdo, M; Moustafa, A; Rabiee, A | 1 |
| Bararpour, N; Darrous, L; Froguel, P; Gasser, M; Gilardi, F; Kutalik, Z; Marques-Vidal, P; Porcu, E; Thomas, A; Waeber, G; Yengo, L | 1 |
| Agah, S; Bitarafan, V; Elovaris, RA; Feinle-Bisset, C; Horowitz, M; Lange, K; Ullrich, SS | 1 |
| Hao, H; Hu, W; Li, J; Li, S; Liu, Z; Lu, Y; Qi, X; Wang, X; Wen, S; Yu, W; Zhou, H | 1 |
| Baum, SJ; Chakravarthy, MV; Chera, H; Gunn, NT; Harrison, SA; Kohli, A; Koziel, MJ; Patil, R; Younes, ZH; Zhao, J | 1 |
| He, X; Wang, L; Wang, S; Yuan, Y; Zhang, Y; Zhong, J; Zhou, Y | 1 |
| Aarnoutse, RE; Burger, DM; Colbers, A; de Kanter, CTMM; Drenth, JPH; Smolders, EJ; Tack, CJ; van Ewijk-Beneken Kolmer, N; Velthoven-Graafland, K; Wolberink, LT | 1 |
| Boerwinkle, E; Chang, P; Coresh, J; Köttgen, A; Rebholz, CM; Selvin, E; Tin, A; Wagenknecht, LE; Yu, B; Zheng, Z | 1 |
| He, T; Ma, X; Nie, C; Zhang, G; Zhang, W | 1 |
| Al-Majdoub, M; Ali, A; Carstensen, B; Ridderstråle, M; Safai, N; Spégel, P; Suvitaival, T; Vestergaard, H | 1 |
| Chang, CT; Chen, CJ; Liao, WL; Lin, YN; Tsai, FJ | 1 |
| Kuusisto, J; Laakso, M; Smith, U; Stancáková, A; Vangipurapu, J | 1 |
| Allam, AS; Hussein, HA; Moaty, ASA | 1 |
| Cong, XD; Dai, DZ; Dai, Y; Ding, MJ; Liu, GL; Zhang, YM | 1 |
| Eckert, S; Freytag, SB; Klebs, SH; Müller, A | 1 |
| Chang, KH; Dikalova, AE; Engberding, N; Griendling, KK; Jo, H; Koga, M; Lassègue, B; Long, JS; Seidel-Rogol, B | 1 |
| Choi, H; Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Oh, PC; Quon, MJ; Sakuma, I; Shin, EK | 1 |
| Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G | 1 |
| Takagi, H; Umemoto, T | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K | 1 |
| Bethel, MA; Califf, RM; Chang, F; Disertori, M; Giles, TD; Haffner, SM; Holman, RR; Latini, R; Maggioni, AP; McMurray, JJ; Rutten, GE; Standl, E; Staszewsky, L; Sun, JL; Thomas, L; Tognoni, G | 1 |
| Asai, S; Kanou, N; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y | 1 |
| Araki, E; Goto, R; Igata, M; Kawasaki, S; Kawashima, J; Kitano, S; Kondo, T; Matsumura, T; Matsuyama, R; Miyagawa, K; Motoshima, H; Ono, K | 1 |
| Bethel, MA; Califf, RM; Charbonnel, B; Diem, P; Haffner, SM; Holman, R; Horton, ES; Krum, H; Leiter, LA; Mareev, V; McMurray, JJ; Reyes, EM; Schaper, F; Shah, BR; Shen, L; Soska, V; Sun, JL; Thomas, L; Wojdyla, D | 1 |
| Xu, C; Xu, J; Zhao, L | 1 |
| Ecder, T | 1 |
| Kondo, M; Miyao, M; Mizuno, Y; Nomura, K; Okuyama, T; Sagawa, N; Sata, A; Tsurutani, Y | 1 |
| Bao, Y; Chen, T; Hu, C; Huang, F; Jia, W; Liu, J; Ma, X; Ni, Y; Xie, G; Zhao, A | 1 |
| Askar, T; Mansour, AA; Mergani, A; Mohammed, MA; Mustafa, AM; Saleh, OM; Zahran, RN | 1 |
| Bao, Y; Chen, T; Hu, C; Huang, F; Jia, W; Ma, X; Ni, Y; Rajani, C; Zhao, A; Zheng, X | 1 |
| Hasegawa, K; Hirata, KI; Ishibashi-Ueda, H; Kono, AK; Mori, S; Morinaga, Y; Nishii, T; Sato, C; Soga, F; Takaya, T; Tanaka, H; Watanabe, Y | 1 |
| Han, JY; Jee, SH; Kim, M; Lee, JH; Lee, SH | 1 |
| Anthony Schork, M; Coca, A; Girerd, X; Hua, TA; Jamerson, K; Julius, S; Kjeldsen, SE; Larochelle, P; Macdonald, T; Mancia, G; McInnes, GT; Schmieder, RE; Viskoper, R; Weber, MA; Widimsky, J; Zanchetti, A | 1 |
| Kohno, N; Nakanishi, S; Nakashima, R; Nojima, H; Ohishi, W; Watanabe, H; Yamane, K; Yoneda, M | 1 |
| Fukushima, H; Hiratate, A; Kitano, K; Munetomo, E; Saito, H; Saito-Hori, M; Takahashi, M; Takaoka, Y; Yamamoto, K | 1 |
| Kashiwagi, A; Maegawa, H; Sawaguchi, M; Uzu, T | 2 |
| Bergmann, A; Bornstein, SR; Fischer, S; Grässler, J; Li, J; Reimann, M; Schulze, J; Schwarz, PE; Selisko, T | 1 |
| Cheng, Q; de Gasparo, M; Law, PK; Leung, PS | 1 |
| Crikelair, N; Lastra, G; Levy, DG; Rocha, R; Seifu, Y; Sowers, JR | 1 |
| Jia, W; Jiang, J; Li, L; Li, M; Liu, L; Wang, F; Wang, N; Zhao, R; Zhao, W; Zheng, T; Zhu, Q | 1 |
| Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y | 1 |
| Chen, X; Dong, Y; Feng, Q; Su, Q; Wang, X; Zhang, H | 1 |
| Hirose, H; Itoh, H; Komiya, N; Saisho, Y; Saito, I | 1 |
| Belousov, DIu; Belousov, IuB; Shestakova, MV | 1 |
| Deedwania, PC; Fonseca, VA; Haffner, SM; Hsueh, WA; Keeling, L; Sica, DA; Sowers, JR; Zappe, DH | 1 |
| Crowley, VE; DeLong, C; Hand, E; Hatunic, M; Nolan, JJ; Stapleton, M | 1 |
| Araki, SI; Haneda, M; Isshiki, K; Kanasaki, M; Kashiwagi, A; Koya, D; Kume, S; Sakaguchi, M; Sugiomoto, T; Uzu, T; Yokomaku, Y | 1 |
| Chou, TC; Chuang, SW; Rick, J | 1 |
| Brennan, AM; Chan, JL; Danias, PG; Khaodhiar, L; Lima, C; Manning, WJ; Mantzoros, CS; Veves, A | 1 |
| Doi, A; Furukawa, Y; Furuta, H; Kusuyama, A; Matsuno, S; Nanjo, K; Nishi, M; Sanke, T; Sasaki, H; Shimada, T; Yasuda, K | 1 |
| Chihara, K; Dan, T; Izuhara, Y; Kurokawa, K; Miyata, T; Ohtomo, S; Robert, A; Tominaga, N; Van Ypersele de Strihou, C | 1 |
| Bao, Y; Jia, W; Qiu, Y; Su, M; Wang, X; Zhao, T | 1 |
| Braga, MF; Leiter, LA | 1 |
| Hollenberg, NK; Meng, X; Parving, HH; Remuzzi, G; Viberti, G; Weir, MR; Zappe, DH | 1 |
| Hotta, H; Ishikawa, S; Itoh, T; Kim, SJ; Kuno, A; Maeda, T; Miki, T; Miura, T; Satoh, T; Shimamoto, K; Tanno, M; Terashima, Y; Togashi, N; Yano, T | 1 |
| Bailey, J; Black, HR; Samuel, R; Zappe, D | 1 |
| Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B | 1 |
| Carter, JD; Cole, BK; Keller, SR; Nadler, JL; Nunemaker, CS; Wu, R | 1 |
| Nathan, DM | 1 |
| Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J | 2 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E | 1 |
| Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E | 1 |
| Blanco-Colio, LM; Carrero, JJ; Celik, T; Egido, J; Eyileten, T; Martín-Ventura, JL; Moreno, JA; Saglam, M; Sonmez, A; Yaman, H; Yenicesu, M; Yilmaz, MI | 1 |
| Kondo, K; Nomura, Y; Oiso, Y; Ozaki, N; Sobajima, H | 1 |
| Scheen, AJ | 1 |
| Dörffel, Y; Kappert, K; Kintscher, U; Kümmel, A; Martus, P; Marx, N; Schimkus, J; Schneider, A; Scholze, J; Stoppelhaar, M; Unger, T; Walcher, D; Winkler, R | 1 |
| Biro, S; Ikeda, Y; Kono, S; Otonari, T; Saikawa, T; Sasaki, J | 1 |
| Luan, FL | 1 |
| Higashi, K; Hiroo, K; Kushiyama, T; Oda, T; Yamamoto, K | 1 |
| Dejima, T; Fujikawa, T; Haku, S; Kanaoka, T; Kondoh, S; Konno, Y; Maeda, A; Mitsuhashi, H; Mizushima, S; Moriya, T; Ogawa, N; Ohsawa, M; Okano, Y; Ozawa, M; Suzuki, D; Tamura, K; Tanaka, K; Toyoda, M; Umemura, S; Umezono, T; Wakui, H; Yamakawa, T; Yanagi, M | 1 |
| Ahn, CM; Choi, SC; Hong, SJ; Kim, JS; Lim, DS; Park, JH | 1 |
| Vértes, A | 1 |
| Hollenberg, NK; Meng, X; Parving, HH; Remuzzi, G; Weir, MR; Zappe, DH | 1 |
| Blaak, EE; Diamant, M; Goossens, GH; Ijzerman, RG; Moors, CC; Serné, EH; van der Zijl, NJ | 1 |
| Atiomo, W; Galazis, N; Haoula, Z; Iacovou, C | 1 |
| Peng, XD; Yang, ZH | 1 |
| Ichimiya, S; Ikeda, N; Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Ohno, M; Shintani, S; Sone, T; Watarai, M; Yamashita, K | 1 |
| Boulton, DW; Chang, M; Griffen, SC; Kasichayanula, S; LaCreta, FP; Liu, X; Shyu, WC | 1 |
| Cao, F; Li, W; Liu, B; Shen, M; Sun, D; Wang, S; Zhang, Z | 1 |
| Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Chen, B; Du, G; Guo, J; Li, X; Qiang, G; Shi, L; Xuan, Q; Yang, H; Yang, X; Zhang, H; Zhang, L; Zhou, D; Zu, M | 1 |
| Nabbi, R; Riess, ML; Woehlck, HJ | 1 |
| Fan, YY; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Mori, H; Nakano, D; Nishiyama, A | 1 |
| Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY | 1 |
| Kariž, S; Nikolajević Starčević, J; Petrovič, D | 1 |
| Imanishi, M; Kitabayashi, C; Konishi, Y; Maeda, I; Masada, M; Morikawa, T; Nishiyama, A; Okada, N; Shirahashi, N; Wilcox, CS | 1 |
| Clish, CB; Deik, AA; Fleischman, A; Gerszten, RE; Grinspoon, SK; McCarthy, MA; McCormack, SE; Mootha, VK; Shaham, O; Wang, TJ | 1 |
| Volpe, M | 1 |
| Brozinick, JT; Grove, K; Hawkins, E; Hoang Bui, H; Kievit, P; Kuo, MS; Tan, B | 1 |
| Alessi, T; Bakris, GL; Oparil, S; Purkayastha, D; Sowers, JR; Yadao, AM | 1 |
| Aizawa, Y; Ikarashi, T; Kaneko, S; Nakagawa, O; Souda, S; Suzuki, K | 1 |
| Viberti, G; Wheeldon, NM | 1 |
| Borovkov, NN; Sidorova, NV | 1 |
| D'Alfonso, R; Federici, M; Frittitta, L; Frontoni, S; Gambardella, S; Lauro, D; Lauro, R; Mariani, LM; Marini, MA; Porzio, O; Sesti, G; Sorge, R; Trischitta, V | 1 |
| Ikuta, H; Nagakura, T; Tanaka, I; Yamazaki, K; Yasuda, N | 1 |
| Borch-Johnsen, K; Drivsholm, T; Echwald, SM; Ekstrøm, CT; Hansen, L; Hansen, T; Nielsen, EM; Pedersen, O | 1 |
| Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV | 1 |
| Cui, TX; Horiuchi, M; Iwai, M; Li, HS; Li, JM; Min, LJ; Okumura, M; Shiuchi, T; Wu, L | 1 |
| Aizawa, Y; Kamimura, T; Kato, K; Soda, S; Suzuki, K | 1 |
| Cucuianu, M; Dican, L | 1 |
| Takeuchi, M; Yamagishi, S | 1 |
| Eguchi, Y; Miura, Y; Oiso, Y; Ozaki, N; Taguchi, S; Tsunekawa, S; Yamamoto, N | 1 |
| Cimpanelli, M; Crespi, C; Gaudio, G; Grandi, AM; Guasti, L; Klersy, C; Riganti, G; Schizzarotto, A; Simoni, C; Venco, A | 1 |
| Fukuhara, S; Iwasaka, T; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A | 1 |
| Inoguchi, T; Kobayashi, K; Maeda, Y; Nakayama, M; Nawata, H; Sasaki, S; Sawada, F; Sonoda, N; Sonta, T; Sumimoto, H; Tsubouchi, H | 1 |
| Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM | 1 |
| Hirose, T; Kawamori, R; Miwa, S; Nakaniwa, T; Ohmura, C; Shimada, S; Shimizu, T; Tamura, Y; Tanaka, Y; Uchino, H; Watada, H | 1 |
| Heljić, B; Velija-Asimi, Z | 1 |
| Hausberg, M; Hohage, H; Kosch, M | 1 |
| Anabitarte, A; Caballero, A; Novoa Novoa, J; Palop, L; Plaza, C; Rodríguez Esparragón, F; Rodríguez Pérez, JC | 1 |
| Böger, RH; Maas, R; Quispe-Bravo, S; Schwedhelm, E; Skamira, C | 1 |
| Dudley, K; Ferran, C; Ganda, O; Hubbard, M; Khaodhiar, L; Lima, C; Scali, S; Shrikhande, G; Veves, A | 1 |
| Ishikawa, H; Katayama, K; Koyabu, S; Murata, T; Nakano, T; Nomura, S | 1 |
| Endo, K; Koide, N; Miyashita, Y; Murano, T; Ohira, M; Oyama, T; Saiki, A; Shirai, K | 1 |
| Adams, F; Boschmann, M; Engeli, S; Franke, G; Jordan, J; Klaua, S; Kreuzberg, U; Luft, FC; Scholze, J; Sharma, AM; Weidinger, G | 1 |
| Hirose, H; Komiya, N; Saisho, Y | 1 |
| Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F | 1 |
| De Ciuceis, C; Endemann, DH; Ko, EA; Pu, Q; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Coca, A; Ekman, S; Girerd, X; Hua, T; Jamerson, K; Julius, S; Kjeldsen, SE; Larochelle, P; MacDonald, TM; Mancia, G; McInnes, GT; Schmieder, RE; Schork, MA; Stolt, P; Viskoper, R; Weber, MA; Widimský, J; Zanchetti, A | 1 |
| Delvin, E; Henderson, M; Lambert, M; Levy, E; Losekoot, M | 1 |
| Savoia, C; Schiffrin, EL; Touyz, RM; Volpe, M | 1 |
| Coll, JR; Estacio, RO; Schrier, RW; Tran, ZV | 1 |
| Chen, SY; Hsiao, PJ; Hsieh, MC; Hsin, SC; Lin, HY; Lin, KD; Lu, YC; Shin, SJ; Wang, CL | 1 |
| Aslanidis, C; Buechler, C; Herfarth, H; Schäffler, A; Wobser, H; Zeitoun, M | 1 |
| Edelsberg, J; Jamerson, K; Khan, ZM; Kjeldsen, SE; Oster, G; Vincze, G; Weycker, D | 1 |
| Itoh, Y; Mori, Y; Tajima, N | 1 |
| Daley, WL; Hollenberg, NK; Kandra, A; Parving, HH; Remuzzi, G; Ritter, S; Rocha, R; Viberti, G; Zelenkofske, S | 1 |
| Davidson, J; Koval, S; Lacourcière, Y; Sharma, AM | 1 |
| Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Mogi, M; Tomono, Y | 1 |
| Allemann, Y; Barbier, M; Ferber, P; Fraile, B; Izzo, JL; Lambert, M | 1 |
| Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Botha, J; DeAngelis, L; Ferber, P; Kandra, A; Karalliedde, J; Mirenda, V; Smith, A; Viberti, G | 1 |
| Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C | 1 |
| Bielinski, SJ; Boerwinkle, E; Bray, MS; Folsom, AR; Kao, WH; Pankow, JS | 1 |
| Fasching, P; Nowotny, P; Parzer, S; Ratheiser, K; Uurzemann, S; Waldhäusl, W | 1 |
| Elbein, SC; Schumacher, MC; Sorensen, LK | 1 |
| Clausen, JO; Echwald, SM; Hansen, L; Hansen, T; Pedersen, O; Rasmussen, SK; Urhammer, SA | 1 |
| Bell, GI; Boutin, P; Chèvre, JC; Demenais, F; Durand, E; Froguel, P; Furuta, H; Hani, EH; Laine, B; Philippi, A; Suaud, L; Velho, G; Vionnet, N | 1 |
| Albu, J; Allison, DB; Burn, P; Chin, W; Deng, N; Duprat, L; Fisher, SL; Franco, LS; Gu, W; Heymsfield, S; Kissebah, A; Kleyn, PW; Lee, J; Maruti, S; Nathan, J; Pi-Sunyer, FX; Tu, Z; Yagaloff, KA | 1 |
| Botteri, F; Cheung, R; Huff, MW; Lewanczuk, RZ; Muirhead, N; Oddou-Stock, P; Pecher, E; Rodger, NW | 1 |
| Karhapää, P; Kärkkäinen, P; Kekäläinen, P; Kuusisto, J; Laakso, M; Miettinen, R; Mykkänen, L; Niskanen, L; Rissanen, J; Uusitupa, M; Wang, H | 1 |
| Coats, AJ | 1 |
| Shimoni, Y | 1 |
| Dunseath, G; Luzio, SD; Owens, DR | 1 |
| Cocozza, S; Ferrara, A; Monticelli, A; Pianese, L; Porcellini, A; Riccardi, G; Varrone, S | 1 |
14 review(s) available for valine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Branched-chain amino acids as a novel biomarker of metabolic disturbances in women with polycystic ovary syndrome - literature review.
Topics: Amino Acids, Branched-Chain; Animals; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Isoleucine; Leucine; Obesity; Polycystic Ovary Syndrome; Prediabetic State; Valine | 2022 |
The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis.
Topics: Amino Acids, Branched-Chain; Biomarkers; Diabetes Mellitus, Type 2; Humans; Isoleucine; Leucine; Valine | 2022 |
Branched Chain Amino Acids: Beyond Nutrition Metabolism.
Topics: Amino Acids, Branched-Chain; Animals; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Isoleucine; Leucine; Metabolic Diseases; Signal Transduction; Valine | 2018 |
Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Obesity, Abdominal; Risk Factors; Tetrazoles; Valine; Valsartan | 2013 |
Renal and metabolic effects of valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Humans; Protective Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2014 |
[Acyclovir-induced neurotoxicity and acute kidney injury in an elderly diabetic patient treated with valacyclovir: report of a case].
Topics: Acute Kidney Injury; Acyclovir; Aged, 80 and over; Antiviral Agents; Consciousness Disorders; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Male; Valacyclovir; Valine | 2014 |
Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Ramipril; Renin-Angiotensin System; Rosiglitazone; Tetrazoles; Thiazolidinediones; Valine; Valsartan; Vasodilation; Ventricular Function | 2009 |
Valsartan: more than a decade of experience.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Meta-Analysis as Topic; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome.
Topics: Adult; Alanine; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hyperglycemia; Lipoproteins, HDL; Metabolomics; Polycystic Ovary Syndrome; Risk; Valine | 2012 |
Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypertension; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Placebos; Prognosis; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2003 |
Coagulation factor XIII and atherothrombosis. A mini-review.
Topics: Arteriosclerosis; Diabetes Mellitus, Type 2; Factor XIII; Fibrinolysis; Humans; Insulin Resistance; Leucine; Metabolic Syndrome; Polymorphism, Genetic; Valine | 2003 |
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Valine; Valsartan | 2001 |
60 trial(s) available for valine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Hepacivirus; Hepatitis C; Humans; Imidazoles; Inflammation; Insulin Resistance; Interleukin-1beta; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.
Topics: Acetylcysteine; Administration, Oral; Arginine; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Glutamine; Humans; Isoleucine; Leucine; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Single-Blind Method; Treatment Outcome; Valine | 2021 |
Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Female; Glucose Tolerance Test; Healthy Volunteers; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Imidazoles; Insulin; Lactic Acid; Male; Metformin; Middle Aged; Octamer Transcription Factor-1; Organic Cation Transporter 2; Pyrrolidines; Therapeutic Equivalency; Valine; Young Adult | 2017 |
Effect of metformin on plasma metabolite profile in the Copenhagen Insulin and Metformin Therapy (CIMT) trial.
Topics: Aged; Carnitine; Chromatography, Liquid; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Isoleucine; Leucine; Lysophospholipids; Male; Mass Spectrometry; Metabolome; Metabolomics; Metformin; Middle Aged; Mitochondria; Tyrosine; Valine | 2018 |
Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Body Mass Index; Brachial Artery; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenotype; Pravastatin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Female; Glucuronidase; Hospitals, University; Humans; Hydrochlorothiazide; Hypertension; Klotho Proteins; London; Male; Middle Aged; Phosphates; Pulse Wave Analysis; Renin-Angiotensin System; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Atrial Fibrillation; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2013 |
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Follow-Up Studies; Humans; Hypertension; Middle Aged; Multivariate Analysis; Regression Analysis; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2008 |
Initial combination therapy compared with monotherapy in diabetic hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
[Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Humans; Hypertension; Irbesartan; Kidney Diseases; Tetrazoles; Valine; Valsartan | 2008 |
Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Metabolic Syndrome; Middle Aged; Prediabetic State; Risk Factors; Tetrazoles; Valine; Valsartan; Young Adult | 2008 |
Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Japan; Losartan; Male; Middle Aged; Prospective Studies; Sodium; Sodium, Dietary; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aorta; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Young Adult | 2009 |
Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria.
Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan | 2010 |
Effect of valsartan on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; C-Reactive Protein; Calcium Channel Blockers; Chi-Square Distribution; Cytokine TWEAK; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Serum Amyloid P-Component; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factors; Turkey; Valine; Valsartan; Vasodilation | 2010 |
Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Hypertension; Insulin Resistance; Lipids; Male; Middle Aged; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
[NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Topics: Angiotensin II Type 1 Receptor Blockers; Belgium; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Interleukin-6; Lipids; Male; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2010 |
Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; beta 2-Microglobulin; Blood Pressure; Blood Urea Nitrogen; Collagen Type IV; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2010 |
[The Shiga Microalbuminuria Reduction Trial].
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Middle Aged; Prospective Studies; Rats; Tetrazoles; Valine; Valsartan | 2010 |
Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
Topics: Adiponectin; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Coronary Stenosis; Diabetes Mellitus, Type 2; Disease Progression; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hypertension; Interleukin-6; Male; Middle Aged; Neointima; Prospective Studies; Single-Blind Method; Sirolimus; Telmisartan; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ultrasonography, Interventional; Valine; Valsartan | 2011 |
Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism.
Topics: Adipokines; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Capillaries; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Inflammation Mediators; Insulin Resistance; Male; Microvessels; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypertension; Japan; Male; Middle Aged; Morbidity; Prospective Studies; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan | 2012 |
Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Topics: Adult; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Simvastatin; Sodium-Glucose Transporter 2 Inhibitors; Tetrazoles; Valine; Valsartan; Warfarin | 2012 |
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Ramipril; Tetrazoles; Valine; Valsartan | 2012 |
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Prospective Studies; Taiwan; Tetrazoles; Time Factors; Treatment Outcome; Uric Acid; Valine; Valsartan | 2012 |
Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Angiotensin Receptor Antagonists; Biopterins; Blood Pressure; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hemodynamics; Humans; Kidney; Male; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Receptors, Angiotensin; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan | 2013 |
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.
Topics: Aged; Amides; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Comorbidity; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fumarates; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypertension; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Cytokines; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Humans; Hypertension; Male; Middle Aged; Monocytes; Tetrazoles; Valine; Valsartan | 2006 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan | 2005 |
The effects of valsartan on lipid profile in normotensive type 2 diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Lipids; Middle Aged; Tetrazoles; Valine; Valsartan | 2005 |
[Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].
Topics: Adult; Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypertension; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2005 |
Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biopsy, Needle; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Male; Microcirculation; Middle Aged; Probability; Prospective Studies; Reference Values; Regional Blood Flow; Risk Assessment; Severity of Illness Index; Skin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypertension; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2006 |
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Ethanol; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tolerance Test; Glycerol; Humans; Hypertension; Insulin; Kinetics; Lactic Acid; Lipids; Male; Metabolism; Middle Aged; Muscle, Skeletal; Obesity; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Atenolol; Biopsy; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diastole; Female; Humans; Hypertension; Male; Middle Aged; Organ Culture Techniques; Subcutaneous Tissue; Systole; Tetrazoles; Time; Treatment Outcome; Valine; Valsartan | 2006 |
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Risk Factors; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Vasodilation | 2007 |
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Colorado; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2006 |
Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART).
Topics: Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Japan; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Obesity; Placebos; Single-Blind Method; Systole; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Retreatment; Tetrazoles; Valine; Valsartan | 2008 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension; Male; Middle Aged; Propafenone; Prospective Studies; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2008 |
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
Insulin production following intravenous glucose, arginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus.
Topics: Adult; Arginine; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Intolerance; Humans; Injections, Intravenous; Insulin; Male; Middle Aged; Valine | 1994 |
The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1999 |
Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes.
Topics: Adolescent; Adult; Antihypertensive Agents; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Tetrazoles; Valine; Valsartan | 2002 |
96 other study(ies) available for valine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Amino acid profile of skeletal muscle loss in type 2 diabetes: Results from a 7-year longitudinal study in asians.
Topics: Amino Acids; Amino Acids, Branched-Chain; Asian People; Diabetes Mellitus, Type 2; Humans; Isoleucine; Leucine; Longitudinal Studies; Muscle, Skeletal; Prospective Studies; Valine | 2022 |
Antihyperglycemic activity of L-norvaline and L-arginine in high-fat diet and streptozotocin-treated male rats.
Topics: Animals; Arginase; Arginine; Diabetes Mellitus, Type 2; Diet, High-Fat; Humans; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Nitric Oxide; Rats; Streptozocin; Valine | 2022 |
Impaired Amino Acid Metabolism and Its Correlation with Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus.
Topics: Asparagine; Betaine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Follow-Up Studies; Humans; Isoleucine; Methionine; Prospective Studies; Valine | 2022 |
NMR-Based Metabolomic Analysis for the Effects of Trimethylamine N-Oxide Treatment on C2C12 Myoblasts under Oxidative Stress.
Topics: Alanine; Catalase; Diabetes Mellitus, Type 2; Glycine; Histidine; Humans; Hydrogen Peroxide; Isoleucine; Leucine; Magnetic Resonance Spectroscopy; Malondialdehyde; Methylamines; Myoblasts; Oxidative Stress; Phenylalanine; Phosphorylcholine; Superoxide Dismutase; Threonine; Valine | 2022 |
Metabolomics analysis of stool in rats with type 2 diabetes mellitus after single-anastomosis duodenal-ileal bypass with sleeve gastrectomy.
Topics: Alanine; Amino Acids, Aromatic; Amino Acids, Branched-Chain; Anastomosis, Surgical; Animals; Bile Acids and Salts; Blood Glucose; Diabetes Mellitus, Type 2; Gastrectomy; Glutamates; Glycated Hemoglobin; Ileum; Isobutyrates; Lithocholic Acid; Obesity, Morbid; Phenylalanine; Phospholipids; Proline; Rats; Streptozocin; Valine | 2022 |
Urinary Metabolomics Study on the Protective Role of Cocoa in Zucker Diabetic Rats via
Topics: Amino Acids, Branched-Chain; Animals; Blood Glucose; Cacao; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Flavonoids; Glycated Hemoglobin; Isoleucine; Ketone Bodies; Leucine; Male; Metabolomics; Proton Magnetic Resonance Spectroscopy; Rats; Rats, Zucker; Valine | 2022 |
Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin.
Topics: Animals; Autophagy; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Leucine; Liver; Mice; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Valine | 2022 |
Metabolic role of the hepatic valine/3-hydroxyisobutyrate (3-HIB) pathway in fatty liver disease.
Topics: Diabetes Mellitus, Type 2; Haemophilus influenzae type b; Humans; Lipid Metabolism; Lipids; Liver; Non-alcoholic Fatty Liver Disease; Reactive Oxygen Species; RNA, Messenger; Valine | 2023 |
Sex-Specific Correlation Analysis of Branched-Chain Amino Acids in Dietary Intakes and Plasma among Chinese Adults.
Topics: Amino Acids, Branched-Chain; Case-Control Studies; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diet; East Asian People; Female; Humans; Isoleucine; Leucine; Male; Middle Aged; Prospective Studies; Valine | 2023 |
Metabolomic profiling of amino acids study reveals a distinct diagnostic model for diabetic kidney disease.
Topics: Amines; Amino Acids; Chromatography, Liquid; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Histidine; Humans; Tandem Mass Spectrometry; Valine | 2023 |
Characteristics of amino acid profiles and incretin hormones in patients with gallstone disease: a pilot study.
Topics: Adult; Aged; Cholecystolithiasis; Diabetes Mellitus, Type 2; Female; Humans; Incretins; Isoleucine; Leucine; Lysine; Male; Metabolic Diseases; Middle Aged; Pilot Projects; Valine | 2019 |
Metabolomics profiles associated with HbA1c levels in patients with type 2 diabetes.
Topics: Aged; Amino Acids; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; Glycine; Hexoses; Humans; Insulin Resistance; Male; Metabolomics; Middle Aged; Phosphatidylcholines; Valine | 2019 |
A High Level of Circulating Valine Is a Biomarker for Type 2 Diabetes and Associated with the Hypoglycemic Effect of Sitagliptin.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Hypoglycemic Agents; Mice; Sitagliptin Phosphate; Valine | 2019 |
Low brain-derived neurotrophic factor protein levels and single-nucleotide polymorphism Val66Met are associated with peripheral neuropathy in type II diabetic patients.
Topics: Adult; Aged; Amino Acid Substitution; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Genetic Predisposition to Disease; Genotype; Humans; Male; Methionine; Middle Aged; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Valine | 2020 |
Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
Topics: Antiviral Agents; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Triangulating evidence from longitudinal and Mendelian randomization studies of metabolomic biomarkers for type 2 diabetes.
Topics: Adult; Aged; Betaine; Biomarkers; Carnitine; Case-Control Studies; Diabetes Mellitus, Type 2; Early Diagnosis; Female; Genetic Predisposition to Disease; Glutamic Acid; Humans; Leucine; Lysine; Male; Mannose; Mendelian Randomization Analysis; Metabolome; Middle Aged; Valine | 2021 |
Comparative Effects of the Branched-Chain Amino Acids, Leucine, Isoleucine and Valine, on Gastric Emptying, Plasma Glucose, C-Peptide and Glucagon in Healthy Men.
Topics: Adult; Amino Acids, Branched-Chain; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Humans; Insulin; Isoleucine; Leucine; Male; Middle Aged; Postprandial Period; Valine; Whey Proteins; Young Adult | 2021 |
Effects of
Topics: Aged; Amino Acids, Branched-Chain; Cardiovascular Diseases; China; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Incidence; Isoleucine; Leucine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Polymorphism, Single Nucleotide; Protein Phosphatase 2C; Valine | 2021 |
Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Biomarkers, Tumor; Body Mass Index; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chromatography, Liquid; Diabetes Mellitus, Type 2; Diagnosis, Differential; Early Detection of Cancer; Feasibility Studies; Female; Humans; Isoleucine; Leucine; Lipid Metabolism; Male; Mass Spectrometry; Metabolic Networks and Pathways; Metabolome; Metabolomics; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Principal Component Analysis; Sensitivity and Specificity; Serologic Tests; Valine | 2017 |
Serum metabolomic profile of incident diabetes.
Topics: Amino Acids, Branched-Chain; Asparagine; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Type 2; Erythritol; Female; Glucose; Humans; Isoleucine; Lactic Acid; Leucine; Male; Maryland; Metabolome; Middle Aged; Minnesota; Mississippi; North Carolina; Prospective Studies; Risk Factors; Trehalose; Valine | 2018 |
Identification of Urinary Metabolite Biomarkers of Type 2 Diabetes Nephropathy Using an Untargeted Metabolomic Approach.
Topics: Aged; Albuminuria; Area Under Curve; Biomarkers; Blood Glucose; Chromatography, Liquid; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fasting; Female; Glycated Hemoglobin; Guanosine; Humans; Male; Metabolomics; Middle Aged; Principal Component Analysis; Ribonucleosides; Tandem Mass Spectrometry; Valine; Xanthines | 2018 |
Nine Amino Acids Are Associated With Decreased Insulin Secretion and Elevated Glucose Levels in a 7.4-Year Follow-up Study of 5,181 Finnish Men.
Topics: Aged; Alanine; Amino Acids; Aspartic Acid; Blood Glucose; Diabetes Mellitus, Type 2; Finland; Follow-Up Studies; Glutamic Acid; Humans; Insulin Resistance; Insulin Secretion; Isoleucine; Leucine; Male; Metabolomics; Middle Aged; Phenylalanine; Risk Factors; Tryptophan; Tyrosine; Valine | 2019 |
Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Topics: Antiviral Agents; Blood Glucose; Carbamates; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Egypt; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Risk Factors; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Male hypogonadism induced by high fat diet and low dose streptozotocin is mediated by activated endoplasmic reticulum stress and IκBβ and attenuated by argirein and valsartan.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Combinations; Endoplasmic Reticulum Stress; Hypogonadism; I-kappa B Proteins; Male; Rats; Rats, Sprague-Dawley; Sexual Behavior, Animal; Streptozocin; Tetrazoles; Valine; Valsartan | 2013 |
The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Bone Morphogenetic Proteins; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Male; Mice; Mice, Mutant Strains; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan; Vasculitis | 2013 |
Concerns for the heart failure reduction in the NAGOYA HEART Study based on meta-regression from the evidence.
Topics: Amlodipine; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypertension; Male; Tetrazoles; Valine | 2013 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Logistic Models; Losartan; Male; Middle Aged; Multivariate Analysis; Olmesartan Medoxomil; Retrospective Studies; Telmisartan; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan | 2013 |
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Topics: Adamantane; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Homeodomain Proteins; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Nitriles; Phlorhizin; Pyrrolidines; Tetrazoles; Trans-Activators; Valine; Valsartan; Vildagliptin | 2013 |
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Models, Statistical; Nateglinide; Phenylalanine; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Autoantibodies against β1 receptor and AT1 receptor in type 2 diabetes patients with left ventricular dilatation.
Topics: Aged; Antihypertensive Agents; Autoantibodies; Biomarkers; Diabetes Mellitus, Type 2; Dilatation, Pathologic; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Metoprolol; Middle Aged; Predictive Value of Tests; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, beta-1; Risk Factors; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan | 2014 |
Branched-chain and aromatic amino acid profiles and diabetes risk in Chinese populations.
Topics: Adult; Aged; Amino Acids, Aromatic; Amino Acids, Branched-Chain; China; Chromatography, Liquid; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Isoleucine; Leucine; Longitudinal Studies; Male; Mass Spectrometry; Middle Aged; Phenylalanine; Risk Factors; Tyrosine; Valine; Young Adult | 2016 |
Glutathione S-Transferase Pi-Ile 105 Val Polymorphism and Susceptibility to T2DM in Population from Turabah Region of Saudi Arabia.
Topics: Adult; Aged; Amplified Fragment Length Polymorphism Analysis; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genetic Predisposition to Disease; Glutathione S-Transferase pi; Humans; Isoleucine; Middle Aged; Polymorphism, Single Nucleotide; Saudi Arabia; Valine | 2016 |
Tryptophan Predicts the Risk for Future Type 2 Diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Case-Control Studies; China; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Insulin; Insulin Resistance; Isoleucine; Leucine; Longitudinal Studies; Male; Middle Aged; Phenylalanine; Predictive Value of Tests; Prognosis; Risk Factors; Tryptophan; Tyrosine; Valine | 2016 |
An Isolated Case of Late-onset Amyloidogenic Transthyretin Type Familial Amyloid Polyneuropathy Associated with a Mutant Transthyretin Substituting Methionine for Valine at Position 30 Showing Latent Progressive Cardiac Involvement Confirmed by Serial Ann
Topics: Aged; Amyloid Neuropathies, Familial; Asian People; Cardiomegaly; Diabetes Mellitus, Type 2; Diagnosis, Differential; Electrocardiography; Humans; Japan; Male; Methionine; Valine | 2017 |
The metabolites in peripheral blood mononuclear cells showed greater differences between patients with impaired fasting glucose or type 2 diabetes and healthy controls than those in plasma.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Metabolism Disorders; Humans; Inflammation Mediators; Leucine; Leukocytes, Mononuclear; Lysophosphatidylcholines; Male; Metabolomics; Middle Aged; Proline; Valine | 2017 |
Manganese superoxide dismutase Ala16Val polymorphism is associated with the development of type 2 diabetes in Japanese-Americans.
Topics: Alanine; Amino Acid Substitution; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Japan; Male; Middle Aged; Polymorphism, Genetic; Reactive Oxygen Species; Superoxide Dismutase; United States; Valine | 2008 |
Synthesis and structure-activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
Topics: Animals; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Mice; Proline; Structure-Activity Relationship; Valine | 2008 |
The A98V single nucleotide polymorphism (SNP) in hepatic nuclear factor 1 alpha (HNF-1alpha) is associated with insulin sensitivity and beta-cell function.
Topics: Adult; Alanine; Diabetes Mellitus, Type 2; Female; Genetic Linkage; Genotype; Hepatocyte Nuclear Factor 1-alpha; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Polymorphism, Single Nucleotide; Valine | 2008 |
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]
Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Drug Therapy, Combination; Fibrosis; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Pyrrolidines; Reactive Oxygen Species; Tetrazoles; Valine; Valsartan | 2008 |
The manganese superoxide dismutase Val16Ala polymorphism is associated with decreased risk of diabetic nephropathy in Chinese patients with type 2 diabetes.
Topics: Aged; Alanine; Alleles; Asian People; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Genetic Predisposition to Disease; Humans; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Risk; Superoxide Dismutase; Valine | 2009 |
A Leu184Val polymorphism in PCK1 gene is associated with type 2 diabetes in Eastern Chinese population with BMI<23 kg/m2.
Topics: Aged; Amino Acid Substitution; Animals; Body Mass Index; Case-Control Studies; China; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Female; Genetic Linkage; Humans; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Phosphoenolpyruvate Carboxykinase (GTP); Polymorphism, Single Nucleotide; Transfection; Valine | 2009 |
Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adiponectin; Aged; Albuminuria; Antihypertensive Agents; Aryldialkylphosphatase; Biomarkers; C-Reactive Protein; Carotid Arteries; Diabetes Mellitus, Type 2; Dinoprost; Female; Glycation End Products, Advanced; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Tetrazoles; Valine; Valsartan | 2008 |
The Leu262Val polymorphism of presenilin associated rhomboid like protein (PARL) is associated with earlier onset of type 2 diabetes and increased urinary microalbumin creatinine ratio in an Irish case-control population.
Topics: Age of Onset; Albuminuria; Amino Acid Substitution; Animals; Case-Control Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Genetic Variation; Gerbillinae; Humans; Hyperinsulinism; Ireland; Leucine; Metalloproteases; Mitochondrial Proteins; Polymorphism, Single Nucleotide; Reference Values; Valine | 2009 |
Electrochemical characterisation of a conductive polymer molecularly imprinted with an Amadori compound.
Topics: Biosensing Techniques; Boronic Acids; Diabetes Mellitus, Type 2; Electrochemical Techniques; Glycated Hemoglobin; Glycosylation; Humans; Molecular Imprinting; Polymers; Tin Compounds; Valine | 2009 |
SUMO4 Met55Val polymorphism is associated with coronary heart disease in Japanese type 2 diabetes individuals.
Topics: Aged; Amino Acid Substitution; Autoantibodies; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Genetic Predisposition to Disease; Glutamate Decarboxylase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Methionine; Middle Aged; Reference Values; Small Ubiquitin-Related Modifier Proteins; Valine | 2009 |
Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypertension; Linear Models; Male; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2009 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Lactic Acid; Lysine; Metabolomics; Metformin; Piperidines; Rosiglitazone; Thiazolidinediones; Uric Acid; Valine | 2009 |
Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Diabetes Mellitus, Type 2; Enkephalin, Leucine-2-Alanine; Erythropoietin; Immunosuppressive Agents; Ischemic Preconditioning, Myocardial; Janus Kinase 2; Losartan; Male; Myocardial Reperfusion Injury; Myocardium; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred OLETF; Receptor, Angiotensin, Type 1; Receptors, Opioid, delta; Signal Transduction; Species Specificity; Tacrolimus; Tetrazoles; Up-Regulation; Valine; Valsartan | 2010 |
Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animal Feed; Animals; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Gene Expression; Glucose Intolerance; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Macrophages; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mitochondria; Tetrazoles; Valine; Valsartan | 2010 |
Navigating the choices for diabetes prevention.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tetrazoles; Valine; Valsartan | 2010 |
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Synergism; Fumarates; Kidney Glomerulus; Losartan; Male; Mice; Mice, Inbred C57BL; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2010 |
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.
Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure | 2010 |
Effect of valsartan on the incidence of diabetes.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Diuretics; Humans; Hypertension; Incidence; Tetrazoles; Valine; Valsartan | 2010 |
Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
Topics: Albuminuria; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; Indoles; Kidney; Lipids; Male; Middle Aged; Pilot Projects; Prospective Studies; Regression Analysis; Tetrazoles; Valine; Valsartan | 2011 |
[The significance of generic valsartan in the treatment of patients].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drugs, Generic; Humans; Hypertension; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Collagen Type I; Collagen Type III; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Hydroxyproline; Insulin Resistance; Male; Myocardium; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2010 |
The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice.
Topics: Adamantane; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Endothelial Cells; Endothelium, Vascular; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Inflammation; Intercellular Adhesion Molecule-1; Mice; NADPH Oxidases; Oxidative Stress; Pyrrolidines; Receptors, Glucagon; Tetrazoles; Valine; Valsartan; Vascular Cell Adhesion Molecule-1 | 2012 |
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Gene Expression Regulation; Hepatocytes; In Situ Nick-End Labeling; Liver Cirrhosis, Experimental; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
Angiotensin-receptor-blocker-induced refractory hypotension responds to methylene blue.
Topics: Aged; Angiotensin Receptor Antagonists; Carbazoles; Carvedilol; Citalopram; Crystalloid Solutions; Diabetes Mellitus, Type 2; Drug Resistance; Female; Gastric Bypass; Humans; Hypotension; Isotonic Solutions; Obesity, Morbid; Phenylephrine; Preoperative Care; Propanolamines; Tetrazoles; Valine; Valsartan | 2012 |
Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fumarates; Kidney; Male; Mice; Mice, Inbred C57BL; Renin; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2012 |
Association of manganese superoxide dismutase and glutathione S-transferases genotypes with myocardial infarction in patients with type 2 diabetes mellitus.
Topics: Alanine; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Genetic Predisposition to Disease; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Lipids; Logistic Models; Male; Middle Aged; Myocardial Infarction; Oxidative Stress; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Risk Factors; Slovenia; Superoxide Dismutase; Valine; White People | 2012 |
Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents.
Topics: Adolescent; Amino Acids, Branched-Chain; Biomarkers; Blood Glucose; Body Mass Index; Child; Child Nutrition Disorders; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Insulin; Insulin Resistance; Insulin Secretion; Isoleucine; Leucine; Longitudinal Studies; Male; Massachusetts; Obesity; Predictive Value of Tests; Valine | 2013 |
Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet.
Topics: Animals; Biomarkers; Ceramides; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Disease Progression; Fructose; Insulin Resistance; Macaca mulatta; Male; Metabolic Syndrome; Obesity; Risk Factors; Serine C-Palmitoyltransferase; Sphingolipids; Valine | 2013 |
[24-hour arterial hypertension profile and heart rhythm variability in patients with arterial hypertension and NIDDM].
Topics: Angiotensin-Converting Enzyme Inhibitors; Circadian Rhythm; Diabetes Mellitus, Type 2; Enalapril; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes.
Topics: Adult; Aged; Alleles; Aspartic Acid; Cohort Studies; Diabetes Mellitus, Type 2; Fibroblasts; Gene Frequency; Glycine; Heterozygote; Humans; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; Leucine; Middle Aged; Phosphoproteins; Polymorphism, Genetic; Valine | 2003 |
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
Topics: Actins; Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Insulin; Male; Mice; Mice, Inbred C57BL; Peptide Fragments; Proglucagon; Protease Inhibitors; Protein Precursors; Pyrroles; Valine | 2003 |
Evidence for an association between the Leu162Val polymorphism of the PPARalpha gene and decreased fasting serum triglyceride levels in glucose tolerant subjects.
Topics: Adult; Aged; Alleles; Blood Glucose; Body Constitution; Case-Control Studies; Denmark; Diabetes Mellitus, Type 2; DNA Mutational Analysis; Fasting; Female; Gene Frequency; Genetic Variation; Glucose Tolerance Test; Heterozygote; Humans; Insulin; Male; Middle Aged; Point Mutation; Polymorphism, Genetic; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides; Valine; White People | 2003 |
Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Crosses, Genetic; Deoxyglucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Intake; Gene Expression Regulation; Glucose Transporter Type 4; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Obese; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphoproteins; Phosphorylation; Protein Processing, Post-Translational; Protein Transport; Pyridines; Signal Transduction; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2004 |
The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Echocardiography; Female; Glycated Hemoglobin; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2004 |
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2004 |
[VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Sodium Chloride Symporter Inhibitors; Tetrazoles; Time Factors; Valine; Valsartan | 2004 |
[VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks].
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Randomized Controlled Trials as Topic; Reference Values; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2004 |
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; PPAR gamma; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enalapril; Humans; Hypertension; Lipids; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2005 |
Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Body Weight; Deoxyguanosine; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Islets of Langerhans; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
N-(carboxymethyl)valine residues in hemoglobin (CMV-Hb) reflect accumulation of oxidative stress in diabetic patients.
Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Hemoglobins; Humans; Male; Middle Aged; Oxidative Stress; Reactive Oxygen Species; Valine | 2005 |
[Hypertension and diabetic nephropathy, a dangerous duo].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Hypertension; Male; Metabolic Syndrome; Ramipril; Tetrazoles; Valine; Valsartan | 2005 |
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Benzimidazoles; Benzoates; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Endothelium, Vascular; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Renal Insufficiency; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glycosylation; Humans; Hypertension; Japan; Tetrazoles; Thiobarbituric Acid Reactive Substances; Valine; Valsartan | 2006 |
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Enalapril; Female; Glycation End Products, Advanced; Mice; Mice, Inbred C57BL; Mice, Obese; Pyridoxamine; Tetrazoles; Valine; Valsartan; Vitamin B Complex | 2006 |
[Lowering blood pressure substantially--and the diabetes risk as well?].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypertension; Sodium Chloride Symporter Inhibitors; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Prevalence and clinical phenotype of the p.Val226Met glucokinase gene mutation in French Canadians in Quebec, Canada.
Topics: Adult; Amino Acid Substitution; Child; Child, Preschool; Diabetes Mellitus, Type 2; Female; France; Glucokinase; Humans; Male; Methionine; Middle Aged; Mutation, Missense; Phenotype; Prevalence; Quebec; Valine | 2007 |
SUMO4 M55V variant is associated with diabetic nephropathy in type 2 diabetes.
Topics: Amino Acid Substitution; Codon; Diabetes Mellitus, Type 2; Diabetic Nephropathies; DNA Primers; Genetic Variation; Humans; Methionine; Polymorphism, Single Nucleotide; Small Ubiquitin-Related Modifier Proteins; Valine | 2007 |
Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases.
Topics: Amino Acid Substitution; Aspartic Acid; Chronic Disease; Cohort Studies; Cytokines; Diabetes Mellitus, Type 2; Female; Gene Frequency; GPI-Linked Proteins; Humans; Inflammatory Bowel Diseases; Lectins; Male; Mutation, Missense; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Reference Values; Valine; White People | 2007 |
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Databases, Factual; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Assessment; Risk Factors; Risk Reduction Behavior; Tetrazoles; Time Factors; Treatment Outcome; United States; Valine; Valsartan | 2007 |
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Calcium Channel Blockers; Cell Size; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Intra-Abdominal Fat; Male; Obesity; PPAR gamma; Random Allocation; Rats; Rats, Long-Evans; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
[Valsartan: arguments for the high dose concept].
Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Humans; Hypertension, Renal; Proteinuria; Tetrazoles; Valine; Valsartan | 2006 |
Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
Topics: Adipocytes, White; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Cell Differentiation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gene Deletion; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2008 |
Lack of association between uncoupling protein-2 Ala55Val polymorphism and incident diabetes in the atherosclerosis risk in communities study.
Topics: Alanine; Atherosclerosis; Cohort Studies; Diabetes Mellitus, Type 2; Female; Genetic Linkage; Genotype; Humans; Incidence; Ion Channels; Male; Middle Aged; Mitochondrial Proteins; Polymorphism, Single Nucleotide; Residence Characteristics; Risk; Uncoupling Protein 2; Valine | 2008 |
Methionine for valine substitution in exon 17 of the insulin receptor gene in a pedigree with familial NIDDM.
Topics: Adult; Alleles; Base Sequence; Diabetes Mellitus, Type 2; Exons; Female; Haplotypes; Humans; Male; Methionine; Molecular Sequence Data; Mutation; Pedigree; Polymorphism, Genetic; Receptor, Insulin; Valine | 1993 |
The Val985Met insulin-receptor variant in the Danish Caucasian population: lack of associations with non-insulin-dependent diabetes mellitus or insulin resistance.
Topics: Blood Glucose; C-Peptide; Denmark; Diabetes Mellitus, Type 2; Genetic Variation; Genotype; Heterozygote; Homozygote; Humans; Insulin; Insulin Resistance; Methionine; Point Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Receptor, Insulin; Reference Values; Valine; White People | 1997 |
A missense mutation in hepatocyte nuclear factor-4 alpha, resulting in a reduced transactivation activity, in human late-onset non-insulin-dependent diabetes mellitus.
Topics: Age of Onset; Animals; Apolipoprotein C-III; Apolipoproteins C; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; COS Cells; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Female; Glucose Tolerance Test; Hepatocyte Nuclear Factor 1; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 1-beta; Hepatocyte Nuclear Factor 4; Humans; Insulin; Insulin Secretion; Isoleucine; Male; Middle Aged; Nuclear Proteins; Pedigree; Phosphoproteins; Point Mutation; Thymidine Kinase; Tissue Distribution; Transcription Factors; Transcriptional Activation; Valine | 1998 |
Identification and functional analysis of novel human melanocortin-4 receptor variants.
Topics: Adolescent; Adult; Amino Acid Substitution; Animals; Body Mass Index; Cloning, Molecular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Genetic Variation; Genotype; Humans; Isoleucine; Male; Methionine; Mice; Middle Aged; Obesity; Pedigree; Polymorphism, Single-Stranded Conformational; Receptor, Melanocortin, Type 4; Receptors, Peptide; Recombinant Proteins; Threonine; Valine | 1999 |
Variants in the hepatocyte nuclear factor-1alpha and -4alpha genes in Finnish and Chinese subjects with late-onset type 2 diabetes.
Topics: Adult; Age of Onset; Aged; Alanine; Amino Acid Substitution; Asian People; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; C-Peptide; China; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Exons; Female; Finland; Genetic Variation; Glucose Tolerance Test; Hepatocyte Nuclear Factor 1; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 1-beta; Hepatocyte Nuclear Factor 4; Humans; Male; Middle Aged; Nuclear Proteins; Phosphoproteins; Polymerase Chain Reaction; Transcription Factors; Valine; White People | 2000 |
Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes.
Topics: Action Potentials; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Electric Conductivity; Isoquinolines; Mutation; Potassium Channels; Quinapril; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Angiotensin, Type 2; Receptors, Cell Surface; Receptors, Leptin; Saralasin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2001 |
Mutations in insulin-receptor gene. Val996 allele in white NIDDM patients.
Topics: Alleles; Amino Acid Sequence; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Receptor, Insulin; Valine; White People | 1992 |